15
Participants
Start Date
April 30, 2011
Primary Completion Date
August 31, 2011
Study Completion Date
August 31, 2011
eptacog alfa (activated)
A review of retrospectively longitudinal data gathered in the routine follow-up from a subset of patients who underwent EOS in studies F7HAEM/USA/3/USA and F7HAEM/USA/4/USA (NCT01561391). Data will be compiled, analysed, and reported in aggregate form.
Novo Nordisk Clinical Trial Call Center, Princeton
Lead Sponsor
Novo Nordisk A/S
INDUSTRY